The indications for receiving ADT were as follows: 19 patients had metastatic things prostate cancer, 8 patients had comorbidities (cardiac failure, n = 3; chronic obstructive pulmonary disease, n = 4; chronic renal insufficiency, n = 1) that put them at high risk, and the others were older according to life expectancy. Five of the older patients had locally advanced disease. The patients were also divided into two groups��GnRH + AA group and orchiectomy + AA group��and 12-month outcomes were compared.A paired t-test was used for the repeated measures showing normal distribution to compare pre- and posttreatment values. The Wilcoxon sum of rank test was used for the measures that did not distribute normally. To compare one-year results between the groups, an ANOVA test was used.
The Mann-Whitney U test was applied for one-year comparison of the TG measures that were not normally distributed. The results were evaluated using the Statistical Package for the Social Sciences (SPSS) version 20.0 (SPSS Inc., Chicago, IL, USA). A P value <0.5 was considered statistically significant.3. ResultsThe mean age of the patients was 74 �� 7 years. Table 1 shows the basic characteristics of the patients regarding lipid profiles and FBG levels in the pretreatment period and after 3-, 6-, and 12-month treatment periods. FBG, TC, and HDL values during ADT are also presented, in Figures Figures1,1, ,2,2, and and3,3, respectively. After 12 months of initiation, a comparison of GnRH + AA and orchiectomy + AA revealed similar outcomes in terms of FBG, TC, HDL, LDL, and TG (P > 0.05).
Figure 1Fasting blood glucose levels during 12-month ADT. FBG: fasting blood glucose, PT: pretreatment, 3M: 3-months; 6M: 6 months; 12M: 12 months.Figure 2TC changes during ADT. TC: total cholesterol, PT: pretreatment, 3M: three months; 6M: six months; 12M: 12 months.Figure 3HDL changes during ADT. HDL: high-density lipoprotein, PT: pretreatment, 3M: 3 months; 6M: 6 months; 12M: 12 months.Table 1Pretreatment and one-year treatment values of FBG levels and lipid profiles.4. DiscussionIn Batimastat this study, we found that the patients receiving ADT had higher TC, LDL cholesterol, and TG levels compared to their own pretreatment levels after three months and through the end of the 12-month initiation of the treatment. HDL cholesterol had a different course during this time; HDL values increased after three months but decreased for the rest of the study period through one year. FBG levels followed a different course; they remained unchanged at six months and increased by 12 months.In a study conducted on 22 patients, Smith et al. observed that a three-month ADT course with GNRH analog + oral cyproterone acetate did not alter lipid profiles or glucose during treatment [13]. However, Dockery et al.